- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
First Helium
Purpose Bitcoin ETF
Black Swan Graphene
Soma Gold Corp.
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
INDIVA
Producing Pharmaceutical-Grade Cannabis for Medical and Recreational Markets
Overview
INDIVA (TSXV:NDVA) is a licensed cannabis producer committed to growing high-quality, medical-grade cannabis in its ‘pharma-grade’ indoor facility in London, Ontario. Having emerged from the partnership between a renowned cannabis grower and a team of finance, legal and retail experts, INDIVA is focused on delivering quality, authenticity and experience through its products.
Unlike a number of its peers, INDIVA has designed the building to have 16 separate, smaller flower rooms so as to be able to apply their proven grow techniques in strictly controlled environments. The updated facility will also host an oil extraction room, allowing the company to further develop its line of oils and extracts. INDIVA expects to receive its sales license in early 2018, enabling the company to begin sales shortly after.
The company is furthering its strategy for developing product-line through a joint venture partnership with Bhang Corporation, an award-winning licensor of cannabis and CBD products. Under this partnership, INDIVA will have access to Bhang’s intellectual property and will run the manufacturing and distribution of a full array of CBD products.
INDIVA Highlights
- Knowledgeable management team with experience in all aspects of cannabis industry
- Licensed producer with patient base of over 1,000 people
- Fully-funded expansion of current facility into 40,000 square-foot operation
- Established joint venture partnership with cannabis and CBD product licensor Bhang Corporation
- Growing operations led by an internationally recognized ‘master grower’
Interactive Chart
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.